Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

31 januari 2014 uppdaterad av: Richard Burt, MD

Umbilical Cord Blood Stem Cell Injection for Critical Limb Ischemia

The purpose of this study is to determine whether treatment with umbilical cord blood stem cells will improve blood flow to the most severely affected leg of a participant with medically refractory and non-surgical peripheral vascular disease of the lower extremity.

Studieöversikt

Status

Avslutad

Detaljerad beskrivning

Umbilical cord blood is a safe alternative source of stem cells used for decades in hematopoietic stem cell transplants for malignancies. There is also a reported decreased incidence of acute GVHD compared to matched unrelated donor transplants.A cord blood registry will be searched for suitable units with compatibility in the ABO and HLA systems. The minimum total nucleated cell dose required which would be 1.0 x 107/kg, and one unit of cells will be procured to meet this requirement. Although it is likely that the transplanted cord blood cells will be rejected over time, we hypothesize that while they remain in the host's tissue these cells will be producing and releasing cytokines, growth factors and other humoral factors that might promote vasculogenesis by stimulating endogenous stem cells and endothelial cells. Since there is no need to collect the patient's own stem cells, the patient's cardiovascular system will not be subjected to any stress due to the leukapheresis procedure itself. No injections of exogenous growth factors, which have been associated with thrombosis, would be required to mobilize the patient's own stem cells. The procedure could conceivably even be performed in its entirety on an outpatient basis.

A total of 25 patients will be enrolled in the study. Patients will be followed for 24 months after the procedure with evaluation visits one day after the transplant and then at one month, six, twelve and twenty four months post-treatment. The visit one day after the transplant will involve a history and physical with a leg exam, a CBC and a chemistry panel to evaluate for possible infection, or other adverse event.

Studietyp

Interventionell

Inskrivning (Faktisk)

1

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Northwestern University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 72 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Atherosclerotic ischemic peripheral vascular disease or Thromboangiitis Obliterans with Critical Limb Ischemia (Fontaine stages III and IV)
  • Participant must match either a or b

    1. Ankle brachial index (ABI) ≤ 0.7
    2. Doppler waveforms at posterior tibial artery and dorsalis pedis artery are monophasic with toe pressure < 30 mmHg.
  • A non-surgical candidate for revascularization e.g. prior vascular reconstruction, inability to locate a suitable vein for grafting, diffuse multi- segment disease, or extensive infra-popliteal disease not amenable to a vascular graft.
  • Age > 18 years old.
  • The non-index leg may be treated only in the event and it full fills the same eligibility criteria and exclusion criteria used in this protocol for the treatment leg.
  • Patients must be on maximal tolerated medical therapy for PVD including A) Cessation of smoking B) Referral to endocrinologist for control of HgA1c to < 7.0 mg/dl, control of hyperlipidemia with statins or other anti-hyperlipidemic drugs as indicated, control of hypertension as indicated C) Antiplatelet therapy with aspirin and / or cilostazol (unless medically contraindicated, e.g. bleeding or allergy)

Exclusion Criteria:

  • Popliteal vascular entrapment syndrome
  • Lower extremity infection or infected ulcer
  • Hypercoagulable state
  • HIV positive
  • HBsAg positive
  • Uncontrolled arrhythmia, that is, persistence of an arrhythmia despite medical therapy
  • Unstable angina
  • Thrombocytopenia < 50,000/ul
  • Leukemia or myelodysplasia
  • Allergy to E coli or its products
  • Patients with metal in their bodies cannot undergo MRIs (MRA). Therefore, patients with, cochlear implants, or aneurysm clips are not eligible. Coronary artery stents are not a contraindication. Patients with pacemakers are still candidates provided they have normal creatinine (< 1.1 mg/dl) and can receive contrast dye (no allergy) for angiogram instead of MRA. MRI/MRA does not need to be repeated if a prior MRA or Angiogram Demonstrates inoperable disease.
  • Patients who are pregnant
  • Poorly controlled diabetes will not be a cause for exclusion but patient must see endocrinologist for better control
  • Current malignancy, except squamous cell or basal cell skin cancers thought to be easily controlled.
  • AST, ALT, or bilirubin more than twice the upper limit of normal.
  • WBC < 2.5 / ul.
  • Any patient who is actively bleeding, including blood on urine dipstick or fecal occult blood.
  • Patient is on chemotherapy or other immuno-suppressive medications such as steroids, cellcept, cyclosporine, cytoxan, azathioprine, rituxan, humira or remicade.
  • Donor is HLA homozygous and shares that HLA haplotype with the recipient (a different donor will have to be found)
  • Patients diagnosed with Thromboangiitis Obliterans (Buerger's Disease) who are smokers and are unwilling or unable to quit smoking
  • A) Patients with a myocardial infarction within the last 30 days or left ventricular ejection fraction < 35% B) Patients with a history of malignancy in the last 5 years (other than basal cell carcinoma or carcinoma in situ) C) Patients with a CVA within the last 6 months D) Patients with a HbA1c level > 7.0%

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: UBC injection into one leg of PVD pt
25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.

The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.

Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois).

Andra namn:
  • HSCT

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Ankle brachial index (ABI), a 15% increase will be considered improvement
Tidsram: Pre-transplant, 1, 6, 12 and 24 months after
Pre-transplant, 1, 6, 12 and 24 months after
Healing of ischemic ulcers
Tidsram: Pre-transplant, 1, 6, 12 and 24 months after
Pre-transplant, 1, 6, 12 and 24 months after
Decreased pain level as reported by the patient
Tidsram: Pre-transplant, 1, 6, 12 and 24 months after
Pre-transplant, 1, 6, 12 and 24 months after

Sekundära resultatmått

Resultatmått
Tidsram
SF-36 quality of life (QOL)
Tidsram: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Walking Impairment Questionnaire
Tidsram: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Increase in pain free ambulation time on treadmill by more than 25%
Tidsram: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Increase in four meter walk or six minute walk by more than 25%
Tidsram: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Richard Burt, MD, Northwestern University and Northwestern Memorial Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 november 2009

Primärt slutförande (Faktisk)

1 januari 2014

Avslutad studie (Faktisk)

1 januari 2014

Studieregistreringsdatum

Först inskickad

19 november 2009

Först inskickad som uppfyllde QC-kriterierna

24 november 2009

Första postat (Uppskatta)

25 november 2009

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

3 februari 2014

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

31 januari 2014

Senast verifierad

1 januari 2014

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • PVD.Cord.Blood.2008

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera